Rallybio Corp

RLYB Nasdaq SEC CIK 1739410
Follow Rallybio Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Revenue, last quarter $0 −100% vs same quarter last year
Net income $43.7M +550% vs same quarter last year
EPS, diluted $7.53 +3522.7% vs same quarter last year
Operating cash flow $45.9M +648% vs same quarter last year
Revenue by quarter
$299K
$38K
$212K
$212K
$212K
$222K
$212K
$0
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$80M−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$9M
FY24−$57.8M
FY23−$74.6M
FY22−$66.7M
FY21−$47M
FY20−$26.4M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25-
FY24−$49.3M
FY23−$60.3M
FY22−$57.3M
FY21−$45.9M
FY20−$22.2M
FY19-

News

No stories filed under Rallybio yet - coverage appears here as the news feed clusters it.